IPP Bureau
Vivimed Labs to manufacture, market Favipiravir tablets
By IPP Bureau - May 11, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
By IPP Bureau - May 11, 2021
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Alembic reports net profit of Rs. 71.94 Cr in Q4FY21
By IPP Bureau - May 11, 2021
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
DCGI approves anti-COVID drug developed by DRDO
By IPP Bureau - May 10, 2021
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Remdesivir allocation made upto 16th May: Gowda
By IPP Bureau - May 10, 2021
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Jubilant Pharma wins over Bracco's legal appeals in the US Court of Appeals
By IPP Bureau - May 10, 2021
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India
By IPP Bureau - May 10, 2021
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib
By IPP Bureau - May 10, 2021
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Lupin enters into agreement with Lilly to expand access for COVID-19
By IPP Bureau - May 10, 2021
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Zydus Wellness reports Rs. 133.13 Cr consolidated PAT in Q4FY21
By IPP Bureau - May 10, 2021
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.
Roche receives emergency use authorisation of COVID-19 drug
By IPP Bureau - May 07, 2021
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Lonza announces expansion plans for mammalian manufacturing facilities
By IPP Bureau - May 07, 2021
The facility is expected to be completed in 2024
PerkinElmer to donate 1 million rapid COVID-19 antigen test kits in India
By IPP Bureau - May 07, 2021
Much-needed diagnostics supplies will help accelerate testing capabilities of hospitals and clinics across India
Alembic announces USFDA approval for two drugs
By IPP Bureau - May 06, 2021
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA
Govt. allocates 16.5 lakh vials of Remdesivir between May 3-9
By IPP Bureau - May 06, 2021
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
